In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d

Behnood Bikdeli; David A Garcia

doi:10.7326/J21-0020

In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d

Ann Intern Med. 2022 Feb;175(2):JC16. doi: 10.7326/J21-0020. Epub 2022 Feb 1.

Authors

Behnood Bikdeli¹, David A Garcia²

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA (B.B.).
² University of Washington, Seattle, Washington, USA (D.A.G.).

PMID: 35099997
DOI: 10.7326/J21-0020

Abstract

Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400. 34649864.

Publication types

Kommentar

MeSH terms

Anticoagulants / adverse effects
COVID-19*
Heparin* / adverse effects
Hospitalization
Humans
Intensive Care Units
SARS-CoV-2

Substances

Anticoagulants
Heparin